CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Dosing 1: Atomoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05101122
NCT05101122Phase 2Completed
CompareCT.gov

Open-Label 4-Period Dose-Escalation Safety and Efficacy Study of AD313 in Participants With Obstructive Sleep Apnea

Apnimed·interventional·Posted Nov 1, 2021·Updated Apr 7, 2023

In Brief

A Phase 2 clinical trial evaluating Dosing 1: Atomoxetine and AD313 for Obstructive Sleep Apnea. Completed, enrolled 15 participants across 2 sites.

Detailed Summary

The SEED study is designed to assess the safety and efficacy for Obstructive Sleep Apnea (OSA) of 3 escalating dose combinations of atomoxetine with AD313 compared to baseline and to atomoxetine alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedNov 1, 2021
Enrollment StartOct 19, 2021
Primary CompletionApr 18, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.7 years ago

Interventions

Dosing 1: Atomoxetinedrug

Oral administration at bedtime

AD313drug

Escalating dose of AD313; Oral administration at bedtime